Skip to main content

Table 1 Tumor and women’s characteristics, treatments performed and frequencies of complications, according to detection method

From: Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs

  Screen-detected cancers Interval cancers P-value Total
N % N %   N %
Total women 732 69.3 325 30.7   1057 100.0
Tumor size (n = 936)      <0.001   
  < = 10 mm 198 31.9 40 12.7   238 25.4
 11 to 20 mm 273 44.0 117 37.0   390 41.7
 21 to 50 mm 132 21.3 133 42.1   265 28.3
  > 50 mm 17 2.7 26 8.2   43 4.6
Lymph node involvement (n = 1054)      <0.001   
 Negative 542 74.2 180 55.6   722 68.5
 Positive 188 25.8 144 44.4   332 31.5
Number of positive nodes (n = 870)      <0.05   
  = <3 515 92.5 268 85.6   783 90.0
 4–20 38 6.8 41 13.1   79 9.1
  > 20 4 0.7 4 1.3   8 0.9
Histological type (n = 1050)      <0.001   
 Ductal Infiltrante 531 72.7 242 75.6   773 73.6
 Ductal In situ 81 11.1 12 3.8   93 8.9
 Lobular 63 8.6 36 11.3   99 9.4
 Otros 55 7.5 30 9.4   85 8.1
Focality (n = 894)      0.643   
 Unifocal 487 83.5 256 82.3   743 83.1
 Multifocal and/or multicentric 96 16.5 55 17.7   151 16.9
Histological grade (n = 914)      <0.001   
 I 181 28.8 48 16.8   229 25.1
 II 249 39.6 104 36.4   353 38.6
 III 152 24.2 121 42.3   273 29.9
 Not applicable 46 7.3 13 4.5   59 6.5
Tumor phenotype (n = 769)      <0.001   
 Luminal A 275 56.9 132 46.2   407 52.9
 Luminal B 131 27.1 79 27.6   210 27.3
 HER2 38 7.9 29 10.1   67 8.7
 Triple negative 39 8.1 46 16.1   85 11.1
Age (n = 1057)      <0.001   
 50–54 193 26.4 117 36.0   310 29.3
 55–59 183 25.0 100 30.8   283 26.8
 60–64 211 28.8 67 20.6   278 26.3
 65–70 145 19.8 41 12.6   186 17.6
Charlson index (n = 1057)      0.380   
 0 535 73.1 241 74.2   776 73.4
 1 129 17.6 53 16.3   182 17.2
  > =2 68 9.3 31 9.5   99 9.4
Surgery (n = 1055)      <0.001   
 Radical 119 16.3 107 33.0   226 21.4
 Conservative 612 83.7 217 67.0   829 78.6
Axillary treatment: SLNB and ALNDc (n = 994)      <0.05   
 Only SLNB 201 29.4 67 21.7   268 27.0
 ALND 483 70.6 243 78.4   726 73.0
Neoadjuvant therapy (n = 1057)      <0.001   
 No 701 95.8 247 76.0   948 89.7
 Yes 31 4.2 78 24.0   109 10.3
Adjuvant therapy (n = 1051)      0.387   
 No 16 2.2 10 3.1   26 2.5
 Yes 712 97.8 313 96.9   1025 97.5
Any complicationa (n = 1057) 225 30.7 88 27.1 0.229 313 29.6
Persistent painb (n = 1045) 93 12.9 25 7.8 <0.05 118 11.3
  1. aNumber of women with at least one complication
  2. bNumber of women with persistent pain
  3. cSLNB: sentinel lymph node biopsy. In this category only women with SLNB performed were included. ALND: axillary lymph node dissection. This category includes women with only ALND performed and women with SLNB and ALND